Stratified analyses
| . | Death . | Relapse . | Death or relapse* . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P† . | HR (95% CI) . | P† . | HR (95% CI) . | P† . | |
| IPSS Intermediate-1 | ||||||
| Normal/mild/moderate‡ | 1 | NA | 1 | NA | 1 | NA |
| Severe | 1.3 (0.6-2.6) | .5 | 3.8 (1.2-12.0) | .02 | 1.6 (0.8-3.0) | .19 |
| IPSS Intermediate-2/high | ||||||
| Normal/mild/moderate‡ | 1 | NA | 1 | NA | 1 | NA |
| Severe | 1.7 (0.9-3.5) | .12 | 2.3 (0.9-6.2) | .08 | 2.0 (1.0-3.8) | .04 |
| Marrow myeloblast percentage < 5% | ||||||
| Normal myeloblasts‡ | 1 | NA | 1 | NA | 1 | NA |
| Abnormal myeloblasts | 1.2 (0.6-2.3) | .63 | 3.7 (1.2-11.3) | .02 | 1.4 (0.7-2.5) | .34 |
| . | Death . | Relapse . | Death or relapse* . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P† . | HR (95% CI) . | P† . | HR (95% CI) . | P† . | |
| IPSS Intermediate-1 | ||||||
| Normal/mild/moderate‡ | 1 | NA | 1 | NA | 1 | NA |
| Severe | 1.3 (0.6-2.6) | .5 | 3.8 (1.2-12.0) | .02 | 1.6 (0.8-3.0) | .19 |
| IPSS Intermediate-2/high | ||||||
| Normal/mild/moderate‡ | 1 | NA | 1 | NA | 1 | NA |
| Severe | 1.7 (0.9-3.5) | .12 | 2.3 (0.9-6.2) | .08 | 2.0 (1.0-3.8) | .04 |
| Marrow myeloblast percentage < 5% | ||||||
| Normal myeloblasts‡ | 1 | NA | 1 | NA | 1 | NA |
| Abnormal myeloblasts | 1.2 (0.6-2.3) | .63 | 3.7 (1.2-11.3) | .02 | 1.4 (0.7-2.5) | .34 |